Moderna Adjusts Vaccine Trial Protocol, Delays Start of Testing

Moderna, one of the front-runners in the race to develop an effective SARS-CoV-2 vaccine, is adjusting its clinical trial protocol, which will delay the start of a 30,000 subject human trial on the vaccine, which was scheduled to start July 9. The phase III trial of the vaccine, which is funded by the National Institutes of Health, is still expected to begin at some point in July. One of Moderna’s competitors, Pfizer, is set to begin trials of its own vaccine in July, with AstraZeneca following in August and Johnson & Johnson in September. Click here to learn more.